Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. (HMTXF) generates news that spans biotechnology, clinical development, and commercialization of autologous stem cell therapy for ischemic disease. The company’s updates frequently center on its VesCell (ACP-01) platform, a patient-derived blood-based stem cell therapy that Hemostemix reports has been studied in multiple clinical trials for peripheral arterial disease, chronic limb threatening ischemia, cardiomyopathies, congestive heart failure, angina, total body ischemia, and vascular dementia.
Investors following HMTXF news can expect regular announcements on clinical milestones, regulatory interactions, and physician-led initiatives. Hemostemix has reported the completion of a Phase II clinical trial in chronic limb threatening ischemia, publication of results in peer-reviewed journals, and presentations of long-term outcomes such as limb preservation, wound healing, and mortality data in severe ischemic patient populations. News items also describe plans for a basket protocol Phase I trial in ischemia-related conditions and a scheduled FDA Pre-IND meeting to review the company’s proposed trial design and regulatory pathway.
Corporate developments are another recurring theme in Hemostemix’s news flow. The company issues releases on non-brokered private placements, stock option grants, and capital raises intended to fund regulatory, clinical, and commercialization activities for ACP-01. It also reports on strategic moves such as a clinic roll-up strategy, including letters of intent to acquire cardiology practices that have experience treating patients with ACP-01, as well as the build-out of patient care and clinical operations roles.
Sector-specific coverage includes Hemostemix’s participation in conferences focused on wound healing, diabetic limb salvage, and regenerative medicine, where the company highlights its CLTI and cardiovascular data. For readers tracking HMTXF, this news page offers a consolidated view of scientific, regulatory, financial, and operational updates related to Hemostemix’s autologous stem cell therapy platform.
Hemostemix (OTCQB: HMTXF) completed a pre-IND meeting with the U.S. Food and Drug Administration on January 16, 2026, receiving conditional support for its basket protocol to evaluate ACP-01 across multiple ischemic and vascular-related conditions.
The FDA indicated the approach is acceptable provided Hemostemix includes clearly defined eligibility criteria, addresses patient heterogeneity, and applies rigorous clinical and statistical design. The FDA also supported the company's plan to collect real-world evidence (RWE) from Florida, Canada, and The Bahamas consistent with FDA guidance on privacy, safety, and data integrity. Hemostemix said it will incorporate the FDA feedback in its IND submission and proceed with product comparison validation studies.
Hemostemix (OTCQB: HMTXF) closed a non-brokered private placement on Dec 31, 2025 for aggregate gross proceeds of CDN$480,000 through the issuance of 4,000,000 common shares at $0.12 per share.
Proceeds will be used for general working capital, including advancing regulatory, clinical, and commercialization initiatives for ACP-01 (VesCell), the company’s autologous angiogenic cell therapy platform. All securities are subject to a statutory hold period and the placement is subject to final acceptance by the TSX Venture Exchange.
Hemostemix (OTCQB: HMTXF) appointed Dr. David B. Alper as Multidisciplinary Physician Education Lead and added him to its Scientific Advisory Board, effective January 2026.
Dr. Alper will lead physician education and clinical engagement for VesCell (ACP-01) with three initiatives: clinical practice engagement in Florida, outreach to U.S. schools of podiatric medicine, and multidisciplinary professional forums focused on ischemic disease, patient selection, and procedural integration.
Hemostemix (OTCQB: HMTXF) announced that CEO Thomas Smeenk published a theoretical manuscript introducing the Conformal Consciousness Hypothesis (CCH), proposing a dimensionless invariant A = E/(hν) as a possible relational constant linking General Relativity, Quantum Mechanics, Cosmology, and String Theory.
The paper presents mathematical appendices on conformal transformations and discusses implications for Penrose's Conformal Cyclic Cosmology, non-computability, entanglement, and string vibrational modes. The company frames the work as evidence of the CEO's analytical approach applied to Hemostemix commercialization of VesCell (ACP-01) in markets including Florida, The Bahamas, and Canada. The manuscript is available at ConformalConsciousness.com.
Hemostemix (OTCQB: HMTXF) granted a total of 963,000 stock options on December 11, 2025, subject to regulatory approval.
Of the grant, 663,000 options vest immediately and 330,000 vest 50% on December 11, 2025 and 50% on December 11, 2026. All options carry an exercise price of $0.09 and expire on December 11, 2030. After issuance Hemostemix has 19,124,694 options issued and outstanding. The grant included 663,000 options to directors and officers and relied on specified exemptions under MI 61-101 for valuation and minority approval. The company noted the material change report was not filed at least 21 days prior due to timing.
Hemostemix (OTCQB: HMTXF) announced two corporate developments: the FDA scheduled a Pre-IND meeting on January 16, 2026 to review a Phase I basket clinical trial protocol for ACP-01 covering ischemia-related indications (vascular dementia, ischemic cardiomyopathy, PAD, generalized ischemia); and the company proposed a non-brokered private placement of up to $960,000 (8,000,000 common shares at $0.12), subject to TSXV approval. All securities will have a four-month hold period. Stated use of proceeds includes FDA preparations, clinical operations expansion in Florida, The Bahamas and Canada, and general working capital.
Hemostemix (OTCQB: HMTXF) appointed Shaune Harding, OStJ, RN (non-practicing) as Director of Patient Care & Clinical Operations effective December 4, 2025. Harding will oversee patient onboarding, comprehensive medical-records transfer, multi-year health-journey mapping, continuous wearable-data monitoring (e.g., Fitbit Sense 2), monthly follow-ups, and adverse-event tracking with escalation and formal reporting.
The role covers patient programs in The Bahamas, Florida, and Canada and is described as supporting long-term continuity of care, enabling patient data capture to advance regulatory approval of ACP-01/VesCell.
Hemostemix (OTCQB: HMTXF) will present at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, highlighting clinical data for its cell therapy ACP-01/VesCell in peripheral arterial disease and chronic limb-threatening ischemia (CLTI).
Key disclosed findings include published studies reporting 83% limb salvage, 0% mortality in some cohorts, and reported ulcer size reduction from a mean of 146 mm2 to 0.48 mm2 at 3 months in treated patients. The release notes ACP-01 is available in Florida under SB 1768.
Hemostemix (OTCQB: HMTXF) will attend DFCon 2025 in San Antonio to present clinical outcomes for ACP-01 (VesCell™) and meet clinicians and researchers over three days.
Phase II midpoint results as published by the University of Toronto: 0% mortality and 83% limb preservation at a 4.5-year midpoint for treated subjects; in a subgroup with ulcers (21 treated, 8 placebo) mean ulcer size fell from 146 mm2 to 0.48 mm2 (p = 0.01) by 3 months; no treatment-related complications at one year.
Financing: TSXV approved a non-brokered private placement of $518,440 adding 520,090 units to a previously closed 4,193,000 units; each unit priced at $0.11 and includes one common share plus one warrant exercisable at $0.15 for two years, with an acceleration feature triggered if the 10-day VWAP exceeds $0.185.
Hemostemix (OTCQB: HMTXF) announced a binding Letter of Intent to acquire two cardiology practices from Dr. Roberto Fernandez-de-Castro and Dr. Hector Rosario Figueroa for 2,000,000 common shares each (subject to adjustment and TSXV approval).
The two cardiologists have combined experience treating more than 200 patients with ACP-01 across multiple cardiovascular indications, and will help implement ACP-01 therapy in the Dominican Republic and the Bahamas. Hemostemix says the acquisitions create anchor practices to accelerate commercialization and future trial expansion and to generate predictable patient flow.
The TSXV approved a financing extension to December 1, 2025. To date the company raised $461,230 via 4,193,000 Units at $0.11 per Unit; each Unit includes one share and one warrant exercisable at $0.15 for two years with an accelerated expiry clause.
FAQ
What is the current stock price of Hemostemix (HMTXF)?
What is the market cap of Hemostemix (HMTXF)?
